Leerink Partners Resumes GW Pharma (GWPH) at Outperform

Leerink Partners resumes coverage on GW Pharma (NASDAQ: GWPH) with a Outperform rating and a price target of $162.00.

Analyst Paul Matteis commented, "We are highly positive on the potential uptake trajectory of Epidiolex, the approval for which appears mostly de-risked after 3 successful ph III trials in Dravet Syndrome (DS) & Lennox Gastaut (LGS). As GW approaches the next stage of its life-cycle - where ahead of approval, investors will wonder if GW will sell or launch independently - we believe either path offers an avenue to stock upside. While nascent commercial biotechs tend to pioneer relatively slow product rollouts, we see multiple points of optimism regarding a GW-led global launch: (1) strong clinical profile of, and "hype" surrounding Epidiolex - >1,000 patients on drug today; (2) significant level of unmet medical need in DS, LGS & refractory seizures; (3) small subset of core prescribers - just ~4-5k epileptologists in the US; (4) the experience of CCO Julian Gangoli, who previously ran commercial for Allergan North America."

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $132.68 yesterday.

You May Also Be Interested In

• Teledyne (TDY) PT Lowered to $455 at Needham
• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
• Fortive (FTV) PT Lowered to $83 at RBC Capital